Evidence map›Paper›PMID 41650216›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Variable thresholds for phosphorylation targets of the ERK signaling pathway.

Kristyn Hayashi, Suganya Sekaran, Pelle Simpson, Christopher C Ebmeier, Cole R Michel, Natalie G Ahn

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Variable thresholds for phosphorylation targets of the ERK signaling pathway.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kristyn HayashiDepartment of Biochemistry, University of Colorado, Boulder, CO 80303.ORCID 0000-0002-2080-2401
Suganya SekaranDepartment of Biochemistry, University of Colorado, Boulder, CO 80303.
Pelle SimpsonDepartment of Biochemistry, University of Colorado, Boulder, CO 80303.
Christopher C EbmeierDepartment of Biochemistry, University of Colorado, Boulder, CO 80303.ORCID 0000-0001-7940-6190
Cole R MichelDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Denver-Anschutz Medical Campus, Aurora, CO 80045.
Natalie G AhnDepartment of Biochemistry, University of Colorado, Boulder, CO 80303.ORCID 0000-0002-2690-2630

Funding

Molecular and Cellular Dynamics in Mammalian Signal TransductionR35GM136392 · NIGMS · UNIVERSITY OF COLORADO · PI NATALIE G. AHN · 2020 to 2026
$4.2M
Predoctoral Training Program in Signaling and Cellular Regulation INCLUDE Down Syndrome SupplementT32GM142607 · NIGMS · UNIVERSITY OF COLORADO · PI Sabrina Leigh Spencer, Tin Tin Su · 2021 to 2026
$3.6M
Fusion Lumos Orbitrap System for Quantitative Proteomics and Metabolomics ApplicationsS10OD028538 · OD · UNIVERSITY OF COLORADO DENVER · PI REISDORPH, NICHOLE A · 2021 to 2021
$1.3M
Q Exactive HF Nanoflow LC Mass Spectrometry SystemS10OD025267 · OD · UNIVERSITY OF COLORADO · PI AHN, NATALIE G. · 2018 to 2018
$600k
ABI Elite ESI-QqTOF Mass Spectrometry SystemS10RR026641 · NCRR · UNIVERSITY OF COLORADO · PI AHN, NATALIE G. · 2010 to 2010
$458k
Acquisition of multi-mode, high-resolution, high-sensitivity imaging platformS10OD034218 · OD · UNIVERSITY OF COLORADO · PI ERBSE, ANNETTE H · 2023 to 2023
$153k
HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35GM136392HHS | NIH | National Institute of General Medical Sciences (NIGMS) S10OD025267HHS | NIH | National Institute of General Medical Sciences (NIGMS) S10OD028538HHS | NIH | National Institute of General Medical Sciences (NIGMS) S10RR026641NCRR NIH HHS S10 RR026641NIGMS NIH HHS R35 GM136392NIGMS NIH HHS T32 GM142607NIH HHS S10 OD025267NIH HHS S10 OD028538NIH HHS S10 OD034218
6 · The paper itself

Abstract

Cell fates regulated by ERK respond to different thresholds of signaling strength. In mammalian cells, conditions that activate ERK to submaximal levels are sufficient to sustain proliferation, survival, and transformation, while stimuli that activate ERK to very high levels often lead to cell death or cell cycle arrest. But while this "Goldilocks effect" is well known, the mechanisms have never been fully explained. In particular, threshold responses have been shown at the level of transcription and cell state changes, but whether phosphorylation responses upstream of these events also respond to thresholds is unknown. Here, we used mass spectrometry-based phosphoproteomics to ask if molecular events in the ERK pathway respond to different thresholds of signaling strength, by quantifying changes in phosphorylation of pathway targets against the occupancy of the two activating phosphosites in ERK. The results show that most phosphorylation events track ERK activation faithfully, responding linearly with increasing 2P-ERK occupancy. But some sites respond nonlinearly, reaching maximal phosphorylation when 2P-ERK exceeds lower thresholds (10 to 40%), or increasing substantially after 2P-ERK exceeds higher thresholds (>60%). Low threshold sites are found on transcriptional repressors that facilitate proliferation when inactivated by ERK/ribosomal s6 kinase (RSK) phosphorylation. By contrast, high threshold sites are found on proteins that are recruited to double-stranded DNA breaks and mediate DNA repair. Measurement of phosphorylation occupancies also revealed unexpected differences between cell states not apparent from inhibitor fold-changes. Our findings demonstrate that signaling thresholds exist at the level of the phosphoproteome, providing potential mechanisms for regulating cellular responses to pathway strength.

Indexed as

Extracellular Signal-Regulated MAP KinasesMAP Kinase Signaling SystemAnimalsHumansPhosphoproteinsPhosphorylationProteomicsExtracellular Signal-Regulated MAP KinasesPhosphoproteinsBRAFERKMAP kinasephosphorylation site occupancysignaling thresholds

Identifiers

PMID41650216
PMCPMC12890786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.